SM-164

SM-164 is a cell-permeable Smac mimetic compound. SM-164 binds to XIAP protein containing both the BIR2 and BIR3 domains with an IC50 value of 1.39 nM and functions as an extremely potent antagonist of XIAP.

C[C@H](NC)C(N[C@H]1CCCC[C@](CC[C@H]2C(N[C@@H](C3=CC=CC=C3)C4=CN(CCCCC5=CC=C(CCCCN6N=NC([C@@H](NC([C@@H]7CC[C@@](CCCC[C@@H]8NC([C@@H](NC)C)=O)([H])N7C8=O)=O)C9=CC=CC=C9)=C6)C=C5)N=N4)=O)([H])N2C1=O)=O

[1]Sun H, et al. Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. J Am Chem Soc. 2007 Dec 12;129(49):15279-94.|[2]Lu J, et al. SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. Cancer Res. 2008 Nov 15;68(22):9384-93.Biomed Res Int. 2019 Apr 7;2019:2121357.|Bioorg Chem. 2022: 106339.|Bioorg Chem. 2023 Jun 1;137:106647.|Bioorg Chem. 2024 Jan, 142, 106964.|Bioorg Med Chem. 2023 Aug 15, 91, 117385.|Bioorg Med Chem. 2024 Feb 15:100:117611.|Bioorg Med Chem. 2024 Mar 1:102:117659.|bioRxiv. 2023 Apr 25.|bioRxiv. 2023 Aug 24.|Cell Death Dis. 2024 Oct 18;15(10):759.|Cell Death Dis. 2018 Nov 15;9(12):1140. |Cell Death Discov. 2024 Mar 23;10(1):152.|Cell Res. 2023 Sep 19.|Curr Protoc. 2021 Jun;1(6):e156.|Eur J Med Chem. 2021 Apr 27;220:113484.|Eur J Med Chem. 2022 Jun 5;236:114345.|Eur J Med Chem. 2024 Mar 9, 116304.|Georg Thieme Verlag KG|Int J Biol Macromol. 2023 Jun 13;125373.|J Cell Mol Med. 2023 Aug 29.|J Med Chem. 2022 Oct 26.|J Med Chem. 2023 Feb 23;66(4):3073-3087.|J Med Chem. 2023 Mar 12.|Mater Sci Eng C Mater Biol Appl. 29 December 2021, 112615.|Mol Neurobiol. 2023 Jan 5.|Nature. 2024 Apr;628(8009):835-843.|Patent. US20230192662A1.|Patent. US20240217963A1.|Patent. US20240294508A1.|PLoS Pathog. 2024 Aug 30;20(8):e1012387.|Proc Natl Acad Sci U S A. 2022 Sep 6;119(36):e2117396119.|Research Square Print. 2022 May.|Rheumatology. 2022 Oct 29;keac621.|Sci Immunol. 2024 Jul 12;9(97):eadn0178.|Signal Transduct Target Ther. 2020 Oct 9;5(1):235.|J Ethnopharmacol. 2023 Nov 1:117373.